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Autoimmune diseases like multiple sclerosis (MS) are known to be associated with debil-
itating emotional disorders that manifest long before the flaring of motor dysfunctions.
Given the emerging role of T cells in controlling both emotions and autoimmunity, in this
study we explored possible correlation betweenT cell activation and changes in emotional
behavior in a mouse model of MS. Our results showed a significant increase in blood
circulating T cells as soon as at day 4 post immunization. This lymphocytosis remained
stable with time and preceded the infiltration ofT cell in the CNS.The kinetic ofT cell entry
in the blood matched the kinetic of changes in behavior measured using the open field
test. Treatment with glatiramer acetate, a well-known immunomodulatory drug for MS,
suppressed behavioral changes while retaining the T cells in the draining lymph nodes.
Together these results provide evidence of a positive correlation between the emigration
of T cells in circulation and changes in emotions during chronic inflammatory diseases.
The validation of these findings in the clinic might help to better understand the cause
of the emotional and psychological burden of patients suffering MS or other autoimmune
diseases. Most importantly our study suggests novel therapeutic venues for the treatment
of the emotional changes associated with autoimmunity.
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INTRODUCTION
A wealth of studies in the literature has indicated a significant
increase in emotional changes in patients suffering from multiple
sclerosis (MS) (1–3) as well as from other autoimmune diseases
(4). Major depression (5–7), bipolar depression (2, 8), anxiety (9–
11), alcohol abuse (12, 13), and other substance abuses (14) are all
at an increased prevalence in MS population. These emotional dys-
functions are not simply a reactive psychological response to the
impact of this pathology on the patient’s life style and have been
correlated with the development of MS and other autoimmune
diseases. Indeed, the depression and anxiety rates are higher in MS
than in those patients experiencing other chronic diseases (15). It
is in fact estimated that between 40 and 50% of patients with MS
will experience a type of depression within their lifetime. As con-
sequence of this, MS patients show a higher rate of suicides when
compared to a normal population with most occurring within
5 years of diagnosis (16, 17).
One of the most unexpected aspects of the correlation between
emotional disorders and MS is their association in time. Recent
evidence suggests that depression usually presents before the onset
of MS symptoms or even before diagnosis (9, 18) and with over
a third of MS patients having a family history of depression (19,
20). Indeed, looking at MS patient blogs1,2 as well as at system-
atic epidemiological studies, it is clear that patients often lament
of having suffered panic attack or anxiety over limited period of
1http://www.mssociety.org.uk/forum/everyday-living
2http://www.thisisms.com/forum/
time. In other words, patients suffered from unexpected attacks of
anxiety that did not necessarily correlated with any manifestation
of the disease. In other cases, it seems that these “bouts” of anx-
iety and panic attack precede or follow the same pattern of MS.
Most intriguingly, MS and mental disorders like depression show
a large degree of similarities. Indeed, both can provoke cognitive
impairment, muscle weakness, or tiredness (21–23).
Previous studies, summarized in Table 1, addressed the behav-
ioral modifications occurring in mouse models of MS, the exper-
imental autoimmune encephalomyelitis (EAE). These studies
reported either no changes (24) or an inverse correlation between
social exploration and the rise of inflammatory mediators includ-
ing IL-1, TNF-α, and PGE2 (25). Conversely, Peruga et al. demon-
strated that mice immunized with a suboptimal dose of MOG35–55
(50µg) showed the manifestation of motor impairment at day 60
after immunization and had an increase anxiety-like behavior that
correlated with an increase in the level of TNF-α and with neu-
ronal loss in the hippocampus (26). This was also associated with
a doubled depressive-like behavior in the learned helplessness par-
adigm. In a more recent study, Haji et al. assessed the behavior of
mice subjected to EAE before locomotor defects started to show
(27). Their results suggested firstly that high anxiety indexes in
EAE mice precede the appearance of motor defects and secondly
that TNF-α has a pivotal role in the high anxiety response because
of the ability of this cytokine to cause striatum inflammation and
microglia activation. In addition, intracerebroventricular admin-
istration of etanercept, an inhibitor of TNF-α signaling, resulted
in anxiolytic-like effects in EAE mice.
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Table 1 | Previous studies characterizing behavioral changes in mouse models of EAE.
Pollak et al. (25) Peruga et al. (26) Rodrigues et al. (24) Haji et al. (27) Acharjee et al. (28)
Animals Female SJL/J mice Female C57BL/6 mice Female C57BL/6
mice
Female C57BL/6
mice
Female C57BL/6 mice
EAE protocol 150µg of PLP139–151
15–20×106 activated
lymph node cells i.p.
50µg of MOG35–55
100 ng of PTX i.p.
100µg of MOG35–55
300 ng of PTX i.p.
200µg of MOG35–55
500 ng of PTX i.p.
100µg of MOG35–55
800 ng of PTX i.p.
Onset of
motor deficits
(days)
Not specified Signs of tail weakness
at 60 dpi
Clinical signs of
disease at 11 dpi
Expected at
10–11 dpi [according
to Ref. (29)]
Limp tails at 9–13 dpi
Behavioral
parameters/
paradigms
Food and sucrose intake;
social exploration
Open field; rotarod;
light/dark box; startle
response and pre-pulse
inhibition; learned
helplessness paradigm
Elevated plus maze;
inhibitory avoidance
task; object
recognition task
Open field; elevated
plus maze
Open field; elevated plus
maze; forced swim test;
tail suspension; sociability
test; fear conditioning
Cytokine
levels
IL-1β expression/level
(RT-PCR/ELISA) and TNF-α
expression (RT-PCR); PGE2
production (RIA assay);
brain (cerebellum,
hypothalamus,
hippocampus, brain stem)
IL-6 and TNF-α
expression (RT-PCR);
brain (hippocampus);
15, 29, 41, 59 dpi
– TNF-α levels (ELISA);
Brain (striatum);
10 dpi
IL-1β and TNF-α expression
(RT-PCR); brain
(hippocampus,
hypothalamus, amygdala)
7 dpi
Main results Transient sickness behavior
episodes associated with
EAE attacks; Increased
pro-inflammatory cytokine
levels before the onset of
motor impairment;
decrease in
pro-inflammatory
cytokines at the peak of
the neurological symptoms
Anxiety- and
depression-like
behavior before the
occurrence of motor
deficits; Increased
TNF-α and neuronal loss
in the hippocampus
No differences in
anxiety-like behavior
and memory in
animals induced with
EAE
Anxiety-like behavior
before the
occurrence of motor
deficits; Increased
TNF-α levels and
activated microglia in
the striatum
Anxiety- and
depression-like behavior,
memory loss and
conditioned learning
deficits in early stage of
EAE; elevated levels of
IL-1β and TNF-α in the
hypothalamus and
increased basal plasma
corticosterone levels
All these studies focused on the biochemical and cellular
changes occurring in the CNS while very little has been explored
in terms of possible changes occurring in the periphery such
as in the blood. Indeed, a great deal of studies, including our
own in RAG-1−/− (30), have shown that T cells plays a piv-
otal role in regulating emotion in mice (31–34) as well as in
humans (35, 36) besides being the main drive of autoimmune
diseases.
In this study we set to investigate the correlation between emo-
tional changes and T cell activation during the very early stages
of the EAE. Consistent with the already published experimental
and clinical studies mentioned before, our results confirmed that
emotional changes occur long before the manifestation of motor
dysfunction and within the first days after the immunization.
In addition, we provide evidence of a direct correlation between
changes in behavior and the time-dependent activation and expan-
sion of T cells, thus confirming a very tight crosstalk between
immunity and mental health during the development of chronic
inflammatory diseases.
MATERIALS AND METHODS
MICE
We used 6-week-old male mice for all the experiments. Mice were
housed in groups of six per cage under specific-pathogen-free con-
ditions and with free access to food and water. Mice were housed
for at least 7 days prior to testing. Wild type C57BL/6 mice pur-
chased from Charles River. All experiments were performed during
the light phase of the light-dark cycle and no more than two tests
per day were performed. All tests were conducted under license
from the Home Office and according to the UK Animals (Scientific
Procedures) Act, 1986.
MOG35–55-INDUCED EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS
This model of autoimmunity is mainly driven by T cells and
has been extensively used to investigate the early events that
characterized the development of MS including the activation
of the immune response that precedes the neuronal damage
caused by inflammatory cells (37). Male C57BL/6 mice received
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an intradermal injection of MOG35–55 (300µg) emulsified in
Complete Freund’s adjuvant (CFA) and two doses of pertus-
sis toxin (PTX) at day zero and day 2 as previously reported
(38). The MOG35–55/CFA emulsion was prepared by dissolving
300µg of MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK,
synthesized by Cambridge Research Biochemicals, Cleveland, UK)
in 150µl of PBS and then mixed with 150µl of CFA (Com-
plete Freud’s Adjuvant, Sigma-Aldrich). The resulting suspen-
sion was emulsified using a high-pressure polytron homoge-
nizer. The severity of the disease was scored on a scale of
0–6 with 0= no neurological signs, 1= tail weakness, 2= tail
paralysis, 3= loss of righting reflex (the mouse can no longer
right themselves after being laid on their back), 4= hind leg
paralysis, 5= quadriplegia, and 6= death. In some experiments,
mice were immunized with CFA only or with the antigenic
ovalbumin peptide OVA323–339 (100µg) and received the two
doses of PTX at day 0 and 2. For the treatment with glati-
ramer acetate (GA; Poly Ala, Glu, Lys, Tyr [6:2:5:1], Sigma),
mice were subcutaneously immunized with GA (150µg/100µl
of PBS) every day for 7 days before the immunization with
MOG35–55/CFA. Control mice were administered the same volume
of PBS vehicle.
LEUKOCYTES ISOLATION FROM CENTRAL NERVOUS SYSTEM
Vertebral columns were dissected from the lumbar to the cer-
vical region and washed several times in PBS to remove blood
trace. Spinal cords were extracted by hydro pressure in the
spinal canal by using a 2-ml syringe and 19-gage needle. Sub-
sequently, tissues were torn apart in sterile PBS by mechanical
pressure through a 70-µm mesh cell strainer (Falcon). Mononu-
clear cells and lymphocytes were isolated by density gradient
centrifugation in Percoll (GE Healthcare). In detail, cells were
pelleted at 400 g for 5 min and suspended in a 30% Percoll
solution. The 30% Percoll solution was carefully layered onto a
70% Percoll solution in a ratio 2:1 and centrifuged at 500 g for
30 min. In this density gradient mononuclear cells sediment at
the interface between 30 and 70% Percoll layers. About 2–3 ml
of interface solution was collected only after the fatty layer at
the top of the centrifuge tube was carefully removed. The puri-
fied mononuclear cells were washed twice in RPMI supplemented
with 100 U/ml of penicillin and streptomycin and 10% of FCS
(Invitrogen).
FLOW CYTOMETRIC ANALYSIS
Lymphocytes were stained in 100µl of FACS buffer (PBS con-
taining 5% FCS and 0.02% of NaN3) containing the following
antibodies: anti-CD3 PE-Cy5 (clone 145-2C11, eBioscience), anti-
CD4 FITC (clone GK 1.5, eBioscience), anti-CD8 PE (clone 53-6.7,
eBioscience) as previously reported (39). Cells were labeled with
the appropriate concentration of conjugated antibodies for 1 h at
4°C as previously described. Samples were acquired with FAC-
SCalibur and analyzed using FlowJo™ software (Tree Star, Inc.,
Oregon Corporation). Peripheral blood leukocytes were collected
at different time points after immunization. Briefly, blood samples
were collected by intracardiac puncture performed under anesthe-
sia in syringes containing sodium citrate 3.2% (w/v). Cells were
pellet at 300 g and resuspended in FACS buffer containing 1:500
Fc blocking antibody (anti-mouse CD16/32) and then stained
with anti-CD3 (clone 145-2C11). Red blood cells were lysed with
RBC Lysis Buffer according to the manufacturer’s instruction
(eBioscience).
PLASMA CYTOKINE MEASUREMENT
Blood was collected by intracardiac puncture performed under
anesthesia. Plasma was obtained from the clotted blood by cen-
trifugation (8000 rpm, 5 min) and stored at −80°C before the
assay. Cytokine levels in the same samples were measured (dil.
1:500) using Mouse Th1/Th2/Th17/Th22 16plex Kit FlowCytomix
and according to the manufacturer’s instructions (eBioscience).
OPEN FIELD ACTIVITY TEST
The open field is a test commonly used to assess locomotor,
exploratory, and anxiety-like behavior in laboratory animals. It
is based on the conflict between the spontaneous aversion that
rodents have of the central area of a novel or brightly lit open field
versus their desire to explore new environments (40). The test was
performed as previously described with some modifications (41).
The open field consisted of a white PVC arena (i.e., a plastic rectan-
gular container size 50 cm× 30 cm) divided into 10 cm× 10 cm
squares (n= 15). Mice were brought into the experimental room
15 min before testing. Each mouse was placed in one of the corner
squares facing the wall. A mouse was observed and recorded for
5 min. The total number of squares crossed, latency to the first
rear and the total number of rears were assessed. After each test
the arena was cleaned with water to attenuate and homogenize
olfactory traces.
DATA ANALYSIS
Pairwise comparisons were made by t -test and comparisons of
more than two groups were analyzed using one-way ANOVA.
The differences in behavior between control and immunized mice
were determined using two-way repeated measure ANOVA and
day-by-day Bonferroni post-test. The results were expressed as
mean± SEM. Fit linear regressions and 95% confidence bands
to the means of parameters over time were calculated by Prism
(GraphPad software).
RESULTS
PHASES OF DISEASE IN MOG35–55-INDUCED EAE
Immunization of C57BL/6 mice with MOG35–55/CFA causes a
neurodegenerative inflammatory disease that resembles the pri-
mary progressive form of MS (42, 43). Although the manifesta-
tions of the disease are not always synchronous in all the mice, it is
possible to distinguish three main phases: the pre-onset, the onset,
and the disease phase (Figure 1A). During the pre-onset (day 0–
10), mice do not show any visible motor defects while behavioral
changes are readily visible since day 2 post immunization. At the
onset of the disease (day 10–12), mice develop a weak or flaccid tail
and start to show signs of motor dysfunction. During the disease
phase (day 12–22) mice progressively loose the ability to move the
hind legs and a significant weight loss (up to 10%) occurs. Mice
were tested starting from day 2 (before PTX injection) and every
other day till day 10, i.e., before the occurrence of any motor defect
(Figure 1B).
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FIGURE 1 | Phases of the disease in MOG35–55-induced EAE and
behavioral assessment protocol. The graph in (A) shows a typical pattern
of development of the EAE clinical score with the three main phases of the
disease while the scheme in (B) shows a schematic of the behavioral test
protocol used in the study. The results in (A) are from a single experiment
with n=10 mice and are representative of N =5–6 separate experiments.
CHANGES IN BEHAVIOR IN THE OPEN FIELD TEST
The open field test has been previously used in the majority of
studies assessing anxiety behavior during EAE (see Table 1). We
used this test as read-out system for the behavioral changes at
the early stages of the EAE. The convenience of this test is that it
provides easy and simultaneous measure of multiple parameters
including locomotion, exploration, and anxiety.
As shown in Figure 2, both MOG35–55/CFA immunized mice
and PBS-treated control group showed a gradual and time-
dependent decrease in locomotor activity (between 50 and 35%,
respectively) that became almost stable from day 4 onward
(p< 0.05; Figure 2A). The number of passages through the central
square is considered a measure of anxiety and exploratory activ-
ity in this test. Control mice showed a variable but overall stable
number of central square visits throughout the 8-days of testing.
In contrast, immunized mice showed a significant reduction by
day 2 and a further decrease at day 4. This value also remained
constant for the next 4 days (p< 0.01; Figure 2B).
Rearing in mice and other rodent is an emotional and protec-
tive response to the stress of a new environment; this is a typical
vertical activity that consists in the standing completely erect on
the hind legs. This “risk-assessment” behavior indicates that the
animal is hesitant to move from its present location to a new posi-
tion. In the open field test, the latency to the first rear is considered
a measure of depression and associated anxiety (40, 44). Control
mice did not show any significant changes in the number of rear-
ing (data not shown) or in the latency to the first rear throughout
the time of the experiment. Conversely, immunized mice showed a
steep increase in latency to rearing until day 4 and then a decline to
almost basal level from day 8 (Figure 2C). When we compared the
fold changes versus baseline values of all the parameters we have
measured (Figure A1 in Appendix), the latency to rearing showed
the highest fold change (about fivefold). Most interestingly, this
followed a linear correlation from day 0 to 4 with a slope that
was significantly different from zero [b= 20.51, F(1,15)= 16.26,
p< 0.01; Figure 2D].
BEHAVIORAL CHANGES AT THE EARLY STAGE OF EAE MIRROR THE
EXPANSION AND MOBILIZATION OF T CELLS
To test if the changes in behavior observed in immunized mice
were correlated to early cellular and molecular events that are
important for the development of EAE, we sacrificed mice at day
0, 2 and 4, and 8 and collected peripheral blood and spleens. As
shown in Figure 3, the total number of CD3+ cells in the spleen
peaked at day 4 and then returned to basal level at day 8. No
changes in the percentages of CD4 or CD8 T cell subsets profile
were observed (Figure A2 in Appendix). Similarly, the percentages
and total number of CD3+ cells in peripheral blood increased until
day 4 while starting to decline at day 8. This decline of peripheral
T cell number was even more evident if the mice started to show
signs of disease at day 8.
The reduction of circulating T cells at day 10 coincided with
the expected infiltration in the CNS. Indeed, consistent with other
previously published studies, very few T cells were detected in the
spinal cord of control mice while a significant increase (fourfold)
were found in the same tissues of the EAE mice at day 8 (Figure A3
in Appendix). The percentage of T cells further increased as the
EAE progressed and was directly correlated to the severity of the
disease (data not shown).
T CELL MOBILIZATION AT THE EARLY STAGE OF EAE IS INDEPENDENT
OF PERIPHERAL INFLAMMATORY CYTOKINES AND NOT RELATED TO
IMMUNIZATION WITH CFA
We next investigated whether the time dependent emigration of
T cells in circulation and the changes in behavior we observed
were due to changes in circulating inflammatory cytokines. When
we scanned serum samples for inflammatory or classical T cell
cytokines, only IL-1, IL-18, and GM-CSF could be detected. How-
ever, none of these mediators was differentially modulated over
time (Figure 4) ruling out the possibility that none of cytokines
we have measured (IL-2, IFN-γ, IL-4, IL-5, IL-6, TNF-α, and IL-
17) are released in circulation upon immunization and could be
associated with the changes of rearing latency.
To further demonstrate that the changes in behavior we
observed over time were associated with T cell activation and
not just the effects of CFA, we tested mice immunized with CFA
only or with the immunogenic peptide OVA323–339. We used the
change in latency as this was the parameter that gave us the
highest fold changes and hence most suitable to appreciate any
modulatory effect. This parameter shows the lapse in time to the
first “reactive and solution-seeking” event and suggests a delay
to react to unexpected and novel conditions (the open field) – a
response that is typical of anxious state. As shown in Figure 5,
CFA only immunized mice showed no difference compared to
vehicle-injected mice while OVA323–339 immunized mice showed
a significant (p< 0.05) increase in latency (Figure 5A).
Immunization with CFA only caused a significant increase
in the percentage of CD3+ T cells that was associated with the
expected leukocytosis induced by this treatment. However, mice
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FIGURE 2 | Behavior of MOG35–55-immunized mice in the open field
test. The graphs show the total number of squares crossed (A), number
of central squares entries (B), latency to rearing, and the relative linear
regression (C,D) of control or MOG35–55-immunized mice assessed
during a 5-min test. Values are expressed as mean±SEM for six to
eight mice and are representative of N = 5–6 separate experiments.
*p<0.05, **p<0.01 indicate significant values compared to control
mice.
FIGURE 3 | Expansion and mobilization ofT cells during the early stages
of MOG35–55-induced EAE. The dot plots show the percentages of CD3+ T
cells while the bar graphs show the comparison of the total number of CD3+
T cells in spleen (top panels) or peripheral blood (bottom panels) of control or
MOG35–55-immunized mice. Values are expressed as mean±SEM for three to
four mice. *p<0.05 indicates significant values compared to control mice.
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FIGURE 4 | Levels of inflammatory cytokine in the plasma of MOG35–55-immunized mice. The graphs show the level of the indicated cytokines in the
plasma of control or MOG35–55-immunized mice sacrificed at the indicated time points. The results are representative of n=4 mice.
treated in the same condition but immunized with OVA323–339
showed a further and significant increment in the percentages
and number of circulating T cells (Figures 5B,C, respectively).
Together these results provide a further link between antigenic
stimulation of T cells and emotional response in mice.
GLATIRAMER ACETATE ATTENUATES THE INCREASED DIGGING
LATENCY OF MOG35–55-IMMUNIZED MICE
To further confirm the link between T cell emigration and
increased latency to rearing, we pre-treated mice with a known
immunomodulatory drug that is effective in the treatment of MS.
As shown in Figure 6A, administration of dose of GA that inhibits
the development of EAE (45) (data not shown) caused a significant
reduction in the latency to rearing (p< 0.01). Most importantly,
when we counted the number of T cells in the draining lymph
nodes, we could observed a significant increase in cell number in
mice treated with GA compared to those receiving PBS control
(Figure 6B). This result further suggested that the retaining of T
cells from the circulation significantly influence and mirror the
changes in behavior.
DISCUSSION
Emerging evidences have shown that T cells contribute to func-
tions other than those related to the immune response (30, 33,
46–50). The aim of this study was to explore a possible correla-
tion between T cell activation and behavioral changes that occur
at the early stage of the MOG35–55-induced EAE. Consistent with
previous observations (24, 25, 27, 28, 40) and the results obtained
by Haji et al. (27), immunized mice showed a reduced number of
crossed central squares in the open field and an overall decrease in
exploratory activity as indicated by the reduced number of squares.
The EAE is a classical model of autoimmune diseases where
mice are immunized with an antigen that resembles a tissue com-
ponent of the target organ. Activated antigen presenting cells
present the antigenic MOG35–55 to T cells in the local drain-
ing lymph nodes (37, 42). Clonally activated T cells expand and
then move first into the blood stream and thereafter into “homing
licensing organs” like the lung (51). Here, their membrane make-
up and gene profile change to acquire a “pathogenic” phenotype.
These “licensed” cells are in fact capable of infiltrating the target
organs (spinal cord and brain in this case) and initiate a cascade
of events that ultimately lead to chronic inflammation and tissue
damage (52).
Consistent with this model, our results show that the number
of T cells increases in the spleen of immunized mice and this is
followed by their migration into the bloodstream (time when the
changes in emotional behavior occur) and ultimately into the CNS
(time when the emotional behaviors come back to basal level). In
light of these findings, it is possible to hypothesize that the two
stages of T cell movement, i.e., first in the bloodstream and then
into the CNS, mirror the two stages of MS development: mood
changes first and motor dysfunction later. These events are not
antigen specific (in this case neuronal antigen specific) or a spe-
cific feature of MS. Indeed, the results obtained using another
non-endogenous antigen such as OVA323–339 provided us with
the same findings obtained with the MOG35–55. This highlights
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FIGURE 5 |The increase in latency to rearing relies onT cell antigenic
stimulation. The graph in (A) shows the percentage of latency to rearing of
control, CFA only or OVA323–339-immunized mice. Values are expressed as
mean percentage±SEM of the basal activity for eight to nine mice. The dot
plots (B) show the percentages of CD3+ T cells while the bar graph (C) shows
the comparison of the total number of CD3+ T cells in peripheral blood of
control, CFA only or OVA323–339-immunized mice at day 4. The results are
representative of n=6–8 mice.
FIGURE 6 | Glatiramer acetate inhibits the emotional changes of
MOG35–55-immunized mice. The graph in (A) shows the percentage of
latency to rearing of vehicle-treated non-immunized mice, glatiramer
acetate-(GA), or control PBS-treated mice subjected to MOG35–55-induced EAE
and assessed during the 5-min test. The values are expressed as mean
percentage±SEM of the basal activity for six to eight. **p<0.01 indicates
significant values compared to control mice. The bar graph in (B) shows the
total number of T cells in the draining lymph nodes of glatiramer acetate-(GA)
or control PBS-treated mice subjected to MOG35–55-induced EAE at day 4. The
results are representative of n=6–8 mice.
the importance of T cell priming and expansion rather than
a general inflammation for the emotional changes. Indeed, the
lack of any significant changes in circulating cytokines suggests
that these events are not part of the classical sickness behavior
observed during acute inflammation (53). Further studies, now in
progress in the lab, will verify this hypothesis in other models of
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autoimmune disease such as the collagen-induced arthritis or dou-
ble strand DNA/peptide-induced lupus. The validation of these
findings might indeed explain or provide a “consensus hypothe-
sis” for the high incidence of mood disorders as a common feature
of autoimmune pathologies.
Although we have not explored the passage of T cells through
the lungs in our system, there are some indications that this might
be a likely event. Several studies have already shown that traffick-
ing of T lymphocytes to specific organs, such as the skin and lungs,
is part of the body’s defense mechanism following acute psycho-
logical stress (35, 36, 54). It is interesting to note at this regard that
patients suffering panic and anxiety attack often declare to be “out
of breath” and that problems get “under our skin” when there is
something that we cannot be rid of.
On a more scientific ground, seminal investigations from
Schwartz’s group have recently shown that T lymphocytes migrate
to the brain in response to psychological stress and that their func-
tion there is to alleviate its negative behavioral consequences. In
addition to this, the authors also showed that immunization of T
cells with a CNS-related peptide reduced the stress-induced anxi-
ety and restored levels of BDNF, shown to be important for stress
resilience (55, 56). In light of these findings, it is feasible to hypoth-
esize that the drop in latency we have observed in our study might
be due to the infiltration of T cells in the CNS and concomitant
induction of a protective “resilient response.”
Further studies by Kipnis’s team have provided further insights
on the multiple roles of T cells as homeostatic keepers of CNS
functions. The authors were the first to describe a critical role for
T cell derived IL-4 as key cytokine involved in learning and mem-
ory through regulation of myeloid cells present in the meningeal
space (32, 57). This intriguing new concept has been recently
confirmed by showing improved learning and memory in T cell
deficient SCID mice adoptively transferred with M2 macrophages
(58). Considering the well-known crosstalk between cognition and
emotion regulation (31), it would be interesting to explore the pos-
sible changes in myeloid cell phenotype during the early stages of
the EAE.
Glatiramer acetate, known in the clinic as copaxone, is one of
the most common disease-modifying drugs together with inter-
feron beta. Although its mechanisms of action have not been fully
defined, a great deal of evidence suggests that it acts directly or
indirectly on T cell activation (59–62). When we tested it in our
system, we could clearly see a significant reduction of latency
to rearing (Figure 6). Most interestingly, we also observed that
GA pre-treatment caused a significant retention of T cells in the
periphery compared to control mice. In light of these findings, it is
tempting to speculate that the reduced activation of T cells, while
reducing the signs of motor dysfunctions and the progression of
the disease, it also reduces emotional changes.
In conclusion, the results of this study suggest a further mech-
anism (besides CNS inflammation) for the link between the neu-
ronal and immune systems – more specifically the emotional state
and immune response – during the course of autoimmune dis-
eases like MS. The validation of these results in the clinic, together
with further exploration of the mechanism by which T cells cause
debilitating mood changes during the early stage of MS, might
help to identify alternative immunomodulatory treatments with
reduced impact on the mental well being of these patients.
ACKNOWLEDGMENTS
We would like to thank Dr. Lucy Norling for carefully reading the
manuscript.
REFERENCES
1. Paparrigopoulos T, Ferentinos P, Kouzoupis A, Koutsis G, Papadimitriou GN.
The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect
and behaviour. Int Rev Psychiatry (2010) 22:14–21. doi:10.3109/
09540261003589323
2. Iacovides A, Andreoulakis E. Bipolar disorder and resembling special psy-
chopathological manifestations in multiple sclerosis: a review. Curr Opin Psy-
chiatry (2011) 24:336–40. doi:10.1097/YCO.0b013e328347341d
3. Labuz-Roszak B, Kubicka-Baczyk K, Pierzchala K, Machowska-Majchrzak A,
Skrzypek M. Fatigue and its association with sleep disorders, depressive symp-
toms and anxiety in patients with multiple sclerosis. Neurol Neurochir Pol (2012)
46:309–17. doi:10.5114/ninp.2012.30261
4. Stojanovich L. Stress and autoimmunity. Autoimmun Rev (2010) 9:A271–6.
doi:10.1016/j.autrev.2009.11.014
5. Wang JL, Reimer MA, Metz LM, Patten SB. Major depression and quality of life
in individuals with multiple sclerosis. Int J Psychiatry Med (2000) 30:309–17.
doi:10.2190/PGWT-UXJ0-7UEH-LGRY
6. Benedetti F, Campori E, Colombo C, Smeraldi E. Fluvoxamine treatment of
major depression associated with multiple sclerosis. J Neuropsychiatry Clin Neu-
rosci (2004) 16:364–6. doi:10.1176/appi.neuropsych.16.3.364
7. Feinstein A, Roy P, Lobaugh N, Feinstein K, O’Connor P, Black S. Structural
brain abnormalities in multiple sclerosis patients with major depression. Neu-
rology (2004) 62:586–90. doi:10.1212/01.WNL.0000110316.12086.0C
8. Ybarra MI, Moreira MA, Araujo CR, Lana-Peixoto MA, Teixeira AL. Bipo-
lar disorder and multiple sclerosis. Arq Neuropsiquiatr (2007) 65:1177–80.
doi:10.1590/S0004-282X2007000700016
9. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple
sclerosis patients. Mult Scler (2007) 13:67–72. doi:10.1177/1352458506071161
10. Poder K, Ghatavi K, Fisk JD, Campbell TL, Kisely S, Sarty I, et al. Social
anxiety in a multiple sclerosis clinic population. Mult Scler (2009) 15:393–8.
doi:10.1177/1352458508099143
11. Giordano A, Granella F, Lugaresi A, Martinelli V, Trojano M, Confalonieri P, et al.
Anxiety and depression in multiple sclerosis patients around diagnosis. J Neurol
Sci (2011) 307:86–91. doi:10.1016/j.jns.2011.05.008
12. Quesnel S, Feinstein A. Multiple sclerosis and alcohol: a study of problem drink-
ing. Mult Scler (2004) 10:197–201. doi:10.1191/1352458504ms992oa
13. Sammarco CL. A case study: identifying alcohol abuse in multiple sclerosis.
J Neurosci Nurs (2007) 39:373–6. doi:10.1097/01376517-200712000-00008
14. Hawkes CH. Are multiple sclerosis patients risk-takers? QJM (2005) 98:895–911.
doi:10.1093/qjmed/hci135
15. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft GH. Depres-
sive symptoms and severity of illness in multiple sclerosis: epidemiologic
study of a large community sample. Am J Psychiatry (2002) 159:1862–8.
doi:10.1176/appi.ajp.159.11.1862
16. Gaskill A, Foley FW, Kolzet J, Picone MA. Suicidal thinking in multiple sclerosis.
Disabil Rehabil (2011) 33:1528–36. doi:10.3109/09638288.2010.533813
17. Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, et al. Suicide
risk in multiple sclerosis: a systematic review of current literature. J Psychosom
Res (2012) 73:411–7. doi:10.1016/j.jpsychores.2012.09.011
18. Zabad RK, Patten SB, Metz LM. The association of depression with disease
course in multiple sclerosis. Neurology (2005) 64:359–60. doi:10.1212/01.WNL.
0000149760.64921.AA
19. Sullivan MJ,Weinshenker B, Mikail S, Bishop SR. Screening for major depression
in the early stages of multiple sclerosis. Can J Neurol Sci (1995) 22:228–31.
20. Sullivan MJ, Weinshenker B, Mikail S, Edgley K. Depression before and after
diagnosis of multiple sclerosis. Mult Scler (1995) 1:104–8.
21. Schwid SR, Covington M, Segal BM, Goodman AD. Fatigue in multiple scle-
rosis: current understanding and future directions. J Rehabil Res Dev (2002)
39:211–24.
22. Gupta RK. Major depression: an illness with objective physical signs. World J Biol
Psychiatry (2009) 10:196–201. doi:10.1080/15622970902812072
23. Maes M. An intriguing and hitherto unexplained co-occurrence: depression and
chronic fatigue syndrome are manifestations of shared inflammatory, oxidative
and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry
(2011) 35:784–94. doi:10.1016/j.pnpbp.2010.06.023
Frontiers in Immunology | Inflammation November 2013 | Volume 4 | Article 400 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Piras et al. Emotional changes in multiple sclerosis
24. Rodrigues DH, Vilela Mde C, Lacerda-Queiroz N, Miranda AS, Sousa LF,
Reis HJ, et al. Behavioral investigation of mice with experimental autoimmune
encephalomyelitis. Arq Neuropsiquiatr (2011) 69:938–42. doi:10.1590/S0004-
282X2011000700018
25. Pollak Y, Ovadia H, Orion E,Weidenfeld J,Yirmiya R. The EAE-associated behav-
ioral syndrome: I. Temporal correlation with inflammatory mediators. J Neu-
roimmunol (2003) 137:94–9. doi:10.1016/S0165-5728(03)00075-4
26. Peruga I, Hartwig S, Thone J, Hovemann B, Gold R, Juckel G, et al. Inflamma-
tion modulates anxiety in an animal model of multiple sclerosis. Behav Brain
Res (2011) 220:20–9. doi:10.1016/j.bbr.2011.01.018
27. Haji N, Mandolesi G, Gentile A, Sacchetti L, Fresegna D, Rossi S, et al. TNF-
alpha-mediated anxiety in a mouse model of multiple sclerosis. Exp Neurol
(2012) 237:296–303. doi:10.1016/j.expneurol.2012.07.010
28. Acharjee S, Nayani N, Tsutsui M, Hill MN, Ousman SS, Pittman QJ. Altered
cognitive-emotional behavior in early experimental autoimmune encephali-
tis – cytokine and hormonal correlates. Brain Behav Immun (2013) 33:164–72.
doi:10.1016/j.bbi.2013.07.003
29. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, et al.
Inflammation triggers synaptic alteration and degeneration in experimental
autoimmune encephalomyelitis. J Neurosci (2009) 29:3442–52. doi:10.1523/
JNEUROSCI.5804-08.2009
30. Rattazzi L, Piras G, Ono M, Deacon R, Pariante CM, D’Acquisto F. CD4(+) but
not CD8(+) T cells revert the impaired emotional behavior of immunocom-
promised RAG-1-deficient mice. Transl Psychiatry (2013) 3:e280. doi:10.1038/
tp.2013.54
31. Dolan RJ. Emotion, cognition, and behavior. Science (2002) 298:1191–4.
doi:10.1126/science.1076358
32. Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4 in the brain: a cytokine to remem-
ber. J Immunol (2012) 189:4213–9. doi:10.4049/jimmunol.1202246
33. Kipnis J, Gadani S, Derecki NC. Pro-cognitive properties of T cells. Nat Rev
Immunol (2012) 12:663–9. doi:10.1038/nri3280
34. Damasio A, Carvalho GB. The nature of feelings: evolutionary and neurobio-
logical origins. Nat Rev Neurosci (2013) 14:143–52. doi:10.1038/nrn3403
35. Stefanski V, Peschel A, Reber S. Social stress affects migration of blood T cells
into lymphoid organs. J Neuroimmunol (2003) 138:17–24. doi:10.1016/S0165-
5728(03)00076-6
36. Dhabhar FS. Psychological stress and immunoprotection versus immunopathol-
ogy in the skin. Clin Dermatol (2013) 31:18–30. doi:10.1016/j.clindermatol.
2011.11.003
37. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple
sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol
(2010) 162:1–11. doi:10.1111/j.1365-2249.2010.04143.x
38. Paschalidis N, Iqbal AJ, Maione F, Wood EG, Perretti M, Flower RJ,
et al. Modulation of experimental autoimmune encephalomyelitis by
endogenous annexin A1. J Neuroinflammation (2009) 6:33. doi:10.1186/1742-
2094-6-33
39. Paschalidis N, Huggins A, Rowbotham NJ, Furmanski AL, Crompton T,
Flower RJ, et al. Role of endogenous annexin-A1 in the regulation of thymo-
cyte positive and negative selection. Cell Cycle (2010) 9:784–93. doi:10.4161/cc.
9.4.10673
40. Walsh RN, Cummins RA. The open-field test: a critical review. Psychol Bull
(1976) 83:482–504. doi:10.1037/0033-2909.83.3.482
41. Deacon RM, Croucher A, Rawlins JN. Hippocampal cytotoxic lesion effects
on species-typical behaviours in mice. Behav Brain Res (2002) 132:203–13.
doi:10.1016/S0166-4328(01)00401-6
42. Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune
encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol
(2011) 164:1079–106. doi:10.1111/j.1476-5381.2011.01302.x
43. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I. The rel-
evance of animal models in multiple sclerosis research. Pathophysiology (2011)
18:21–9. doi:10.1016/j.pathophys.2010.04.004
44. Prut L, Belzung C. The open field as a paradigm to measure the effects of
drugs on anxiety-like behaviors: a review. Eur J Pharmacol (2003) 463:3–33.
doi:10.1016/S0014-2999(03)01272-X
45. Smirnov I, Walsh JT, Kipnis J. Chronic mild stress eliminates the neuroprotec-
tive effect of Copaxone after CNS injury. Brain Behav Immun (2013) 31:177–82.
doi:10.1016/j.bbi.2012.12.015
46. Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. T cell deficiency leads to cog-
nitive dysfunction: implications for therapeutic vaccination for schizophrenia
and other psychiatric conditions. Proc Natl Acad Sci U S A (2004) 101:8180–5.
doi:10.1073/pnas.0402268101
47. Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N, et al. Immune cells
contribute to the maintenance of neurogenesis and spatial learning abilities in
adulthood. Nat Neurosci (2006) 9:268–75. doi:10.1038/nn1629
48. Brynskikh A, Warren T, Zhu J, Kipnis J. Adaptive immunity affects learning
behavior in mice. Brain Behav Immun (2008) 22:861–9. doi:10.1016/j.bbi.2007.
12.008
49. Garg SK, Banerjee R, Kipnis J. Neuroprotective immunity: T cell-derived glu-
tamate endows astrocytes with a neuroprotective phenotype. J Immunol (2008)
180:3866–73.
50. Rook GA, Lowry CA, Raison CL. Lymphocytes in neuroprotection, cognition
and emotion: is intolerance really the answer? Brain Behav Immun (2011)
25:591–601. doi:10.1016/j.bbi.2010.12.005
51. Odoardi F, Sie C, Streyl K, Ulaganathan VK, Schlager C, Lodygin D, et al. T cells
become licensed in the lung to enter the central nervous system. Nature (2012)
488:675–9. doi:10.1038/nature11337
52. Kawakami N, Lassmann S, Li Z, Odoardi F, Ritter T, Ziemssen T, et al. The
activation status of neuroantigen-specific T cells in the target organ deter-
mines the clinical outcome of autoimmune encephalomyelitis. J Exp Med (2004)
199:185–97. doi:10.1084/jem.20031064
53. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to
activation of innate immunity. Eur J Pharmacol (2004) 500:399–411. doi:10.
1016/j.ejphar.2004.07.040
54. Viswanathan K, Dhabhar FS. Stress-induced enhancement of leukocyte traffick-
ing into sites of surgery or immune activation. Proc Natl Acad Sci U S A (2005)
102:5808–13. doi:10.1073/pnas.0501650102
55. Lewitus GM, Cohen H, Schwartz M. Reducing post-traumatic anxiety by immu-
nization. Brain Behav Immun (2008) 22:1108–14. doi:10.1016/j.bbi.2008.05.002
56. Lewitus GM, Schwartz M. Behavioral immunization: immunity to self-antigens
contributes to psychological stress resilience. Mol Psychiatry (2009) 14:532–6.
doi:10.1038/mp.2008.103
57. Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, et al.
Regulation of learning and memory by meningeal immunity: a key role for IL-4.
J Exp Med (2010) 207:1067–80. doi:10.1084/jem.20091419
58. Derecki NC, Quinnies KM, Kipnis J. Alternatively activated myeloid (M2) cells
enhance cognitive function in immune compromised mice. Brain Behav Immun
(2011) 25:379–85. doi:10.1016/j.bbi.2010.11.009
59. Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of
glatiramer acetate. J Neuroimmunol (2011) 235:9–17. doi:10.1016/j.jneuroim.
2011.01.009
60. Racke MK, Lovett-Racke AE. Glatiramer acetate treatment of multiple sclero-
sis: an immunological perspective. J Immunol (2011) 186:1887–90. doi:10.4049/
jimmunol.1090138
61. Oreja-Guevara C, Ramos-Cejudo J, Aroeira LS, Chamorro B, Diez-Tejedor E.
TH1/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients
treated with glatiramer acetate or natalizumab. BMC Neurol (2012) 12:95.
doi:10.1186/1471-2377-12-95
62. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis
and beyond. Autoimmun Rev (2013) 12:543–53. doi:10.1016/j.autrev.2012.09.
005
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 22 October 2013; accepted: 08 November 2013; published online: 21 November
2013.
Citation: Piras G, Rattazzi L, McDermott A, Deacon R and D’Acquisto F (2013) Emo-
tional change-associated T cell mobilization at the early stage of a mouse model of
multiple sclerosis. Front. Immunol. 4:400. doi: 10.3389/fimmu.2013.00400
This article was submitted to Inflammation, a section of the journal Frontiers in
Immunology.
Copyright © 2013 Piras, Rattazzi, McDermott , Deacon and D’Acquisto. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
www.frontiersin.org November 2013 | Volume 4 | Article 400 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Piras et al. Emotional changes in multiple sclerosis
APPENDIX
FIGURE A1 | Behavior of MOG35–55-immunized mice in the open field
test. The graphs show the percentage of total number of squares crossed
(A), number of central squares entries (B), and latency to rearing (C) of
control or MOG35–55-immunized mice compared to their baseline levels
assessed during a 5-min test. Values are expressed as mean
percentage±SEM for six to eight mice and are representative of N =5–6
separate experiments. *p< 0.05, **p<0.01, ***p<0.001 indicate
significant values compared to control mice.
FIGURE A2 | CD4/CD8T cell profile of MOG35–55-immunized mice. The dot plots show the percentages of CD4+ and CD8+ T cells in the spleen of control or
MOG35–55-immunized mice sacrificed at the indicated time points. The results are representative of n=6–8 mice.
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FIGURE A3 | Infiltration ofT cells in the CNS of MOG35–55-immunized
mice. The dot plots and bar graph show the comparison of the percentages
and total number of CD3+ T cells infiltrated in the spinal cord of control or
MOG33–55-immunized mice. Values are expressed as mean±SEM for three
mice and are representative of N =3 separate experiments. **p<0.01
indicates significant values compared to control mice.
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